The challenge of targeting metastasis

Cancer and Metastasis Reviews

Volumn 34, Issue 4, 2015, Pages 635-641

  Fidler, Isaiah J ^a   Kripke, Margaret L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biologic heterogeneity; Genetic instability; Metastasis progenitor cell; Organ microenvironment

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; HOMEOSTASIS; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANTINEOPLASTIC AGENT; SIGNAL PEPTIDE;

ANTINEOPLASTIC AGENTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84958940591     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9586-9     Document Type: Article

References (95)

1. American Cancer Society. (2015). Cancer facts and figures (2015). Atlanta: American Cancer Society.
2. Mukherjee, S. S. (2010). The emperor of all maladies. New York: Simon & Schuster.
3. Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research, 70, 5649–5669.
4. Talmadge, J. E., & Fidler, I. J. (2014). Cancer invasion and metastasis. In The pathobiology of human disease: a dynamic encyclopedia of disease mechanisms (pp. 423–433). San Diego: Elsevier.
5. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285, 1182–1186.
6. Nagy, J. A., & Dvorak, H. F. (2012). Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clinical & Experimental Metastasis, 29, 657–662.
7. Sitohy, B., Nagy, J. A., & Dvorak, H. F. (2012). Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Research, 72, 1909–1914.
8. Folkman, J. (1986). How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Research, 46, 467–473.
9. Nakajima, M., Morikawa, K., Fabra, A., Bucana, C. D., & Fidler, I. J. (1990). Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. Journal of the National Cancer Institute, 82, 1890–1898.
10. Liotta, L. A. (1986). Tumor invasion and metastases—role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Research, 46, 107.
11. Liotta, L. A., Kleinerman, J., Catanzaro, P., & Rynbrandt, D. (1977). Degradation of basement membrane by murine tumor cells. Journal of the National Cancer Institute, 58, 1427–1431.
12. 125I-5-iodo-2′-deoxyuridine. Journal of the National Cancer Institute, 45, 773–782.
13. Fidler, I. J. (1973). Selection of successive tumor lines for metastasis. Nature (New Biology), 242, l48–l49.
14. Butler, T. P., & Gullino, P. M. (1975). Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Research, 35, 512–516.
15. Alix-Panabières, C. A., & Pantel, K. (2014). Challenges in circulating tumour cell research. Nature Reviews Cancer, 14, 623–631.
16. Pantel, K., Denève, E., Nocca, D., Coffy, A., Vendrell, J. P., Maudelonde, T., et al. (2012). Circulating epithelial cells in patients with benign colon diseases. Clinical Chemistry, 58, 936–940.
17. Tarin, D., Price, J. E., Kettlewell, M. G., Souter, R. G., Vass, A. C., & Crossley, B. (1984). Mechanisms of human tumor metastasis in patients with peritoneovenous shunts. Cancer Research, 44, 3584–3592.
18. Weiss, L. (1986). Metastatic inefficiency: causes and consequences. Cancer Research, 3, 1–24.
19. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 133, 571–573.
20. Virchow, R. (1858). Die Cellular Pathologie. Berlin: Hirschwald.
21. Hart, I. R., & Fidler, I. J. (1980). Role of organ selectivity in the determination of metastatic patterns of the Bl6 melanoma. Cancer Research, 40, 2281–2287.
22. Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews Cancer, 3, 453–458 (Timeline).
23. Fidler, I. J., & Kripke, M. L. (1977). Metastasis results from preexisting variant cells within a malignant tumor. Science, 197, 893–895.
24. Witz, I. P. (2008). Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Research, 68, 9–13.
25. Fidler, I. J., Kim, S.-J., & Langley, R. R. (2007). The role of the organ microenvironment in the biology and therapy of metastasis. Journal of Cellular Biochemistry, 101, 927–936.
26. Langley, R., & Fidler, I. J. (2011). The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer, 128, 2527–2535.
27. Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9, 239–252.
28. Fidler, I. J. (1995). Modulation of the organ microenvironment for the treatment of cancer metastasis. Journal of the National Cancer Institute, 87, 1588–1592 (Commentary).
29. Blanpain, C., & Fuchs, E. (2014). Plasticity of epithelial stem cells in tissue regeneration. Science, 344, 1243–1254.
30. Yang, T., Rycaj, K., Zhong-min, L., & Tang, D. G. (2014). Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets. Cancer Research, 74, 2922–2927.
31. Nieto, M. A. (2013). Epithelial plasticity: a common theme in embryonic and cancer cells. Science, 342, 708–716.
32. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339, 1546–1558.
33. Merlo, L. M. F., & Maley, C. C. (2010). The role of genetic diversity in cancer. Journal of Clinical Investigation, 120, 401–403.
34. Fidler, I. J. (1978). Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Research, 38, 2651–2660.
35. Wiese, F. W., III, & Maclovor, D. (2014). Tackling cancer’s heterogeneity in 2014. Genetic Engineering & Biotechnology News, 34, 1–2.
36. Burrell, R. A., McGranhan, N., Bartek, J., & Swanson, C. (2013). The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 501, 338–345.
37. Kern, S. (2012). Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Research, 72, 6097–6101.
38. Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., et al. (2010). Signatures of mutation and selection in the cancer genome. Nature, 463, 893–898.
39. Nakamura, T., Kuwai, T., Kitadai, Y., Sasaki, T., Fan, D., Coombes, K. R., & Fidler, I. J. (2007). Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Research, 67, 7597–7604.
40. Kuwai, T., Nakamura, T., Kim, S. J., Sasaki, T., Kitadai, Y., Langley, R. R., et al. (2008). Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors. American Journal of Pathology, 172, 358–366.
41. Wolman, S. R., McMorrow, L. E., Fidler, I. J., & Talmadge, J. E. (1985). Development and progression of karyotypic variability in melanoma K-1735 following X-irradiation. Cancer Research, 45, l839–l844.
42. Harbst, K., Staaf, J., Måsbäck, A., Olsson, H., Ingvar, C., Vallon-Christersson, J., et al. (2010). Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 20, 381–391.
43. Talmadge, J. E., Wolman, S. R., & Fidler, I. J. (1982). Evidence for the clonal origin of spontaneous metastases. Science, 217, 361–363.
44. Hu, F. U., Wang, R. Y., & Hsu, T. C. (1987). Clonal origin of metastasis in B16 murine melanoma: a cytogenetic study. Journal of the National Cancer Institute, 78, 155–163.
45. Talmadge, J. E. (2007). Clonal selection of metastasis within the life history of a tumor. Cancer Research, 67, 11471–11475.
46. Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature, 472, 90–94.
47. Cifone, M. A., & Fidler, I. J. (1981). Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 78, 6949–6952.
48. Kim, M. S., Zhong, Y., Yachida, S., Rajeshkumar, N. V., Abel, M. L., Marimuthu, A., et al. (2014). Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Molecular & Cellular Proteomics, 13, 2803–2811.
49. Bos, P. D., Zhang, X. H., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., et al. (2009). Genes that mediate breast cancer metastasis to the brain. Nature, 459, 1005–1009.
50. Park, E. S., Kim, S. J., Kim, S. W., Yoon, S. L., Leem, S. H., Kim, S. B., et al. (2011). Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proceedings of the National Academy of Sciences of the United States of America, 108, 17456–17461.
51. Jain, S., Zuka, M., Liu, J., Russell, S., Dent, J., Guerrero, J. A., et al. (2007). Platelets glycoprotein Ibα supports experimental lung metastasis. Proceedings of the National Academy of Sciences of the United States of America, 104, 9024–9028.
52. Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumor metastasis. Nature Reviews Cancer, 11, 123–134.
53. Gasic, G. J. (1984). Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Reviews, 3, 99–116.
54. Bambace, N. U., & Holmes, C. E. (2011). The platelet contribution to cancer progression. Journal of Thrombosis and Haemostasis, 9, 237–249.
55. Jayson, G. C., Hicklin, D. J., & Ellis, L. M. (2012). Antiangiogenic therapy—evolving view based on clinical trial results. Nature Reviews. Clinical Oncology, 9, 297–303.
56. Bridges, E., & Harris, A. L. (2015). Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy. Cancer Cell, 27, 7–9.
57. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 15, 232–239.
58. Wong, P. P., Demircioglu, F., Ghazaly, E., Alrawashdeh, W., Stratford, M. R., Scudamore, C. L., et al. (2015). Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell, 27, 123–137.
59. Fidler, I. J., Yano, S., Zhang, R.-D., Fujimaki, T., & Bucana, C. D. (2002). The seed and soil hypothesis: vascularization and brain metastases. Lancet Oncology, 3, 53–57 (Personal view).
60. Ellis, L. M., & Fidler, I. J. (2010). Therapy fails, patients don’t. Nature Medicine, 16, 974–975.
61. Donnem, T., Hu, J., Ferguson, M., Adighibe, O., Snell, C., Harris, A. L., et al. (2013). Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Medicine, 2, 427–436.
62. Qian, C.-N. (2013). Hijacking the vasculature in ccRCC—co-option, remodeling and angiogenesis. Nature, 10, 300–304.
63. Dvorak, H. F. (1986). Wounds that do not heal: similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315, 1650–1659.
64. Riss, J., Khanna, C., Koo, S., Chandramouli, G. V., Yang, H. H., Hu, Y., et al. (2006). Cancers as wounds do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Research, 66, 7216–7224.
65. Jain, R. K. (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine, 7, 987–989.
66. Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58–62.
67. Jain, R. K. (2008). Taming vessels to treat cancer. Scientific American, 298, 56–63.
68. Jain, R. K. (2013). Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. Journal of Clinical Oncology, 31, 2205–2218.
69. Arjaans, M., Oosting, S. F., Schröder, C. P., & de Vries, E. G. (2013). Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Research, 73, 3347–3355.
70. Van der Veldt, A. A., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N., et al. (2012). Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell, 21, 82–91.
71. Keskin, D., Kim, J., Cooke, V. G., Wu, C. C., Sugimoto, H., Gu, C., et al. (2015). Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Reports, 10, 1066–1081.
72. Mendelsohn, J., & Baselga, J. (2006). Epidermal growth factor receptor targeting in cancer. Seminars in Oncology, 33, 369–385.
73. Mendelsohn, J., & Baselga, J. (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology, 21, 2787–2799.
74. Hanahan, D., & Coussens, L. M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell, 21, 309–322.
75. Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420, 860–867.
76. Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013). Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science, 339, 286–291.
77. Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., et al. (2008). Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Research, 68, 918–926.
78. Ozdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R., et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell, 25, 719–734.
79. Chambers, C. A., Krummel, M. F., Boitel, B., Hurwitz, A., Sullivan, T. J., Fournier, S., et al. (1996). The role of CTLA-4 in the regulation and initiation of T cell responses. Immunology Reviews, 153, 27–46.
80. Tang, C., Wang, X., Soh, H., Seyedin, S., Cortez, M. A., Krishnan, S., et al. (2014). Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunology Research, 2, 831–838.
81. Fidler, I. J., & Kleinerman, E. S. (1984). Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under co-cultivation conditions. Journal of Clinical Oncology, 2, 937–943.
82. Kleinerman, E. S., Murray, J. L., Snyder, J. S., Cunningham, J. E., & Fidler, I. J. (1989). Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Research, 49, 4665–4670.
83. Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., et al. (2008). Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. Journal of Clinical Oncology, 26, 633–638.
84. Brown, J. M., & Giaccia, A. J. (1998). The unique physiology of solid tumours: opportunities (and problems) for cancer therapy. Cancer Research, 58, 1408–1416.
85. Tannock, I. F. (1968). The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. British Journal of Cancer, 22, 258–273.
86. Yano, S., Shinohara, H., Herbst, R. S., Kuniyasu, H., Bucana, C. D., Ellis, L. M., et al. (2000). Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Research, 60, 4959–4967.
87. Kim, S.-J., Uehara, H., Yazici, S., Busby, J. E., He, J., Maya, M., et al. (2006). Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. Journal of the National Cancer Institute, 98, 783–793.
88. Sasaki, T., Kitadai, Y., Nakamura, T., Tsan, R. Z., Kuwai, T., Langley, R. R., et al. (2007). Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neoplasia, 9, 1066–1077.
89. Yokoi, K., Kim, S.-J., Thaker, P., Yazici, S., Nam, D.-H., He, J., et al. (2005). Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia, 7, 696–704.
90. Kim, S.-J., Kim, J. S., Kim, S. W., Yun, S. J., He, J., Brantley, E. C., et al. (2012). Antivascular therapy of multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Translational Oncology, 5, 39–47.
91. Fidler, I. J. (2011). The role of the organ microenvironment in brain metastasis. Seminars in Cancer Biology, 21, 107–112.
92. Kim, S.-J., Kim, J. S., Park, E. S., Lee, J. S., Lin, Q., Langley, R. R., et al. (2011). Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia, 3, 286–298.
93. Lin, Q., Balasubramanian, K. K., Fan, D., Kim, S.-J., Guo, L., Wang, H., et al. (2010). Reactive astrocytes protect melanoma cells form chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia, 9, 748–754.
94. Kim, S. W., Choi, H. J., Lee, H.-J., He, J., Wu, Q., Langley, R. R., et al. (2014). Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. Neuro-Oncology, 16, 1585–1598.
95. Klein, A., Schwartz, H., Sagi-Assif, O., Meshel, T., Izraely, S., Ben Menachem, S., et al. (2015). Astrocytes facilitate melanoma brain metastasis via secretion of IL-23. Journal of Pathology, 236, 116–127.